Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow IKT
Inhibikase Therapeutics, Inc. (IKT) EV/Sales
As of 16 October 2026, Inhibikase Therapeutics, Inc. (IKT) trades at a EV/Sales of 495×. Over the past ten years it has ranged from −243× (November 2022) to 1,078× (September 2026); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −20.1× | — |
| FY2022 | −75.5× | — |
| FY2021 | −4.5× | — |
| FY2020 | 61.9× | (41.38%) |
| FY2019 | 106× | 0.00% |
| FY2018 | 106× | 0.00% |
| FY2017 | 106× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | −20.1× | — |
| Sep 2023 | −25.7× | — |
| Jun 2023 | 5.2× | — |
| Mar 2023 | −53.6× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CABA Cabaletta Bio, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | 0.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.6× |
| PRLD Prelude Therapeutics Incorporated compare | 7.5× |
| XFOR X4 Pharmaceuticals, Inc. compare | 12.4× |
| LCTX Lineage Cell Therapeutics, Inc. compare | 14.8× |
| ACIU AC Immune compare | 31.3× |
| IKT Inhibikase Therapeutics, Inc. | 495× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)